

PYC PRESENTING ON DRUG DELIVERY PLATFORM AT OLIGONUCLEOTIDE THERAPEUTIC SOCIETY 2022 MEETING

PERTH, Australia and California, USA – 3 October 2022 – PYC Therapeutics (ASX:PYC) is a biotechnology company combining two complementary platform technologies:

- RNA drug design capabilities; and
- a proprietary drug delivery technology.

Together they are being developed to create a new generation of RNA therapeutics to change the lives of patients with genetic diseases.

PYC today announced an upcoming poster presentation highlighting pre-clinical data from its blinding eye disease programs at the Oligonucleotide Therapeutics Society (OTS) 2022 Annual Meeting taking place in Phoenix, Arizona 2-5 October 2022.

Details for the OTS 2022 video poster presentation are as follows:

Title: “Enhancement of Antisense Oligomer Cell Penetration in Retinal Layers Using a Modular Cell Penetrating Peptide Platform”

Lead Authors: E Woodward, P Cunningham, S Fletcher, K Rice, S Yeung, C Hall, A Martin, H Vo, A Mills. PYC Therapeutics Ltd, Australia

Key Highlights:

- PYC’s proprietary drug delivery technology confers a distinct potency advantage in the inner layers of the mouse retina when compared to the 2’-MOE modified (‘naked’) antisense oligonucleotide of the same sequence
- This improved outcome conferred by PYC’s technology in the inner retina may offer distinct advantages for therapeutics to treat diseases characterised by retinal ganglion cell degeneration – including both Autosomal Dominant Optic Atrophy (ADOA) and glaucoma
- PYC is currently progressing a disease-modifying therapy for the treatment of ADOA towards in-human trials

The poster presentation can be accessed on demand throughout the meeting by conference attendees on the OTS 2022 Annual Meeting website, or on PYC’s website in the Posters and Publications section of the [Pipeline](#) page.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a biotechnology company creating a new generation of RNA therapies by combining its drug design capabilities with a proprietary drug delivery platform.

The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including two programs focused on inherited eye diseases and pre-clinical discovery programs focused on neurodevelopmental and kidney diseases. PYC's discovery, pre-clinical and laboratory operations are located in Australia and its translational, clinical and regulatory operations are located in the United States. For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [Twitter](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited

CONTACTS:

INVESTORS and MEDIA
info@pyctx.com